Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863434 · ClinicalTrials.gov registry record · Phase 2
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00863434 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 2 participants.
The verdict
NCT00863434, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving clofarabine together with cytarabine may kill more cancer cells. PURPOSE: This pilot phase II trial is studying how well giving clofarabine together with cytarabine works in treating patients with acute myeloid leukemia with minimal residual disease
Interventions
- DRUG clofarabine
- BIOLOGICAL filgrastim
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863434
The ClinicalTrials.gov registry entry for NCT00863434 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which clofarabine is the first listed.
NCT00863434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863434 about?
NCT00863434 is a clinical study titled "Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease". RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving clofarabine together with cytarabine may kill more cancer cells. PURPOSE: This pilot phase II t...
What is the current status of trial NCT00863434?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-02.
What interventions are being tested in trial NCT00863434?
The interventions under investigation include: clofarabine (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00863434?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.